上海复旦复华科技股份有限公司 2024 年度营业收入扣除情况表 专项审核报告 永拓会计师事务所（特殊普通合伙） 上海复旦复华科技股份有限公司 2024 年度营业收入扣除情况表专项审核报告 永证专字（2025）第310180号 上海复旦复华科技股份有限公司全体股东： 我们按照中国注册会计师审计准则审计了上海复旦复华科技股份有限公司 (以下简称"复旦复华")2024年度财务报表，包括2024年12月31日的合并及母 公司资产负债表，2024年度的合并及母公司利润表、合并及母公司现金流量表、 合并及母公司股东权益变动表以及财务报表附注，并于2025年4月28日出具了永 证审字（2025）第110027号无保留意见的审计报告。 在对上述财务报表执行审计的基础上，我们接受委托，对后附的复旦复华 2024年度营业收入扣除情况表（以下简称"营业收入扣除情况表"）执行了合理 保证的鉴证业务。 一、管理层的责任 按照《上海证券交易所股票上市规则》以及《上海证券交易所上市公司自律 监管指南第2号-业务办理--第七号财务类退市指标:营业收入扣除》的有关规定 编制营业收入扣除情况表是复旦复华管理层的责任，这种责任包括保证其内容 真实 ...

关于上海复旦复华科技股份有限公司 前期会计差错更正及追溯调整的专项说明的 审核报告 目 录 一、 审核报告 二、 前期会计差错更正及追溯调整的专项说明 永拓会计师事务所(特殊普通合伙) 二、注册会计师的责任 我们的责任是在实施审核工作的基础上对复旦复华管理层编制的《关于上海 复旦复华科技股份有限公司前期会计差错更正及追溯调整的专项说明》发表审核 结论。我们按照中国注册会计师审计准则的规定执行审核工作。中国注册会计师 审计准则要求我们遵守执业道德守则，计划和实施审核工作，对《关于上海复旦 复华科技股份有限公司前期会计差错更正及追溯调整的专项说明》是否不存在重 1 关于上海复旦复华科技股份有限公司 前期会计差错更正及追溯调整的专项说明的 审核报告 永证专字（2025）第310183号 上海复旦复华科技股份有限公司全体股东： 我们接受委托，审核了后附的上海复旦复华科技股份有限公司(以下简称"复 旦复华")管理层编制的《关于上海复旦复华科技股份有限公司前期会计差错更正 及追溯调整的专项说明》。 一、管理层的责任 根据《企业会计准则第28号--会计政策、会计估计变更和差错更正》、中国 证券监督管理委员会《公开发行证券的 ...

关于上海复旦复华科技股份有限公司 前期会计差错更正及追溯调整的专项说明的 审核报告 目 录 一、 审核报告 二、 前期会计差错更正及追溯调整的专项说明 永拓会计师事务所(特殊普通合伙) 关于上海复旦复华科技股份有限公司 前期会计差错更正及追溯调整的专项说明的 审核报告 永证专字（2025）第310183号 上海复旦复华科技股份有限公司全体股东： 我们接受委托，审核了后附的上海复旦复华科技股份有限公司(以下简称"复 旦复华")管理层编制的《关于上海复旦复华科技股份有限公司前期会计差错更正 及追溯调整的专项说明》。 一、管理层的责任 大错报获取合理保证。在审核过程中，我们实施了检查有关会计资料与文件、检 查会计记录以及重新计算等我们认为必要的程序。我们相信，我们的审核工作为 提出审核结论提供了合理的基础。 三、审核结论 我们认为，复旦复华编制的《关于上海复旦复华科技股份有限公司前期会计 差错更正及追溯调整的专项说明》已按照《企业会计准则第28号--会计政策、会 计估计变更和差错更正》、中国证券监督管理委员会《公开发行证券的公司信息 披露编报规则第19号--财务信息的更正及相关披露》及上海证券交易所《上海证 券交易 ...

上海复旦复华科技股份有限公司 舆情管理制度 （2025 年 4 月） 第一章 总则 第一条 为提高上海复旦复华科技股份有限公司（以下简称"公司 "）应对各类舆情 的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司正常生产经营活动、 商业信誉、投资价值等造成的影响，切实保护公司及利益相关方合法权益，根据《上海证券 交易所股票上市规则》等相关法律、法规、规范性文件和《公司章程》的相关规定，结合公 司实际情况，制定本制度。 第二条 本制度所称舆情包括但不限于： （一）报刊、电视、网络等媒体对公司进行的负面报道； （二）已经或将给公司造成不良影响的传言或信息； （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信息； 第五条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。有效监 测、评估、应对和引导内部舆论和社会舆论，减少、消除或避免因媒体报道可能对公司造成 的各种负面影响，切实维护公司的利益和形象。 第六条 公司董事长、总经理、董事会秘书、其他高级管理人员及相关职能部门负责 人共同组成公司应对舆情管理工作的最高组织和决策机构，统一领导公司应对各类舆情的处 （四）其他涉及公司 ...

上海复旦复华科技股份有限公司 2024年度独立董事述职报告 （任永康） 一、独立董事的基本情况 作为公司独立董事，本人拥有专业资质及能力，在从事的专业领域积累了丰 富的经验。本人个人工作履历、专业背景以及任职情况如下： 本人任永康，男，1968年8月出生，汉族，学士学位。曾就职于中国外轮理 货公司、上海港务局、上海交运局、上海外高桥保税区，历任理货员、业务员、 营业部经理、浦西部经理等职务。现任上海航天技术研究院调研员、上海复旦复 华科技股份有限公司独立董事。 本人未在公司担任除独立董事以外的任何职务，也未在公司主要股东公司担 任任何职务，与公司以及主要股东之间不存在利害关系或其他可能妨碍本人进行 独立客观判断的关系，不存在影响独立性的情况。 二、独立董事年度履职概况 1、参加董事会、股东大会情况 任期内，作为上海复旦复华科技股份有限公司（以下简称"公司"）的独立 董事，本人严格遵照《公司法》《证券法》《上海证券交易所股票上市规则》《上 市公司治理准则》等法律法规以及《公司章程》《独立董事工作细则》等规章制 度的规定和要求，以关注和维护全体股东的利益为宗旨，认真、忠实、勤勉地履 行独立董事应尽的职责，客观、独 ...

上海复旦复华科技股份有限公司 对会计师事务所 2024 年度审计履职情况的评估报告 职业风险基金上年度（2024 年末）数：6,485.12 万元； 永拓会计师事务所不存在违反《中国注册会计师职业道德守则》对独立性要 求的情形。 组织形式：特殊普通合伙企业 注册地址：北京市朝阳区关东店北街 1 号 2 幢 13 层 首席合伙人：吕江 永拓会计师事务所具有良好的投资者保护能力，能承担因审计失败导致的民 事赔偿责任，职业风险基金计提、质押保险购买符合相关规定。近三年，永拓会 计师事务所不存在在职业行为相关民事诉讼中承担民事责任的情况。 上海复旦复华科技股份有限公司（以下简称"公司"）聘请永拓会计师事务 所（特殊普通合伙）（以下简称"永拓"）作为公司2024年度审计机构。根据《中 华人民共和国公司法》《中华人民共和国证券法》《国有企业、上市公司选聘会 计师事务所管理办法》和《上海证券交易所上市公司自律监管指引第1号——规 范运作》等相关规范性文件的规定，公司对永拓2024年度履职情况进行了评估， 具体情况汇报如下： 一、2024年年审会计师事务所基本情况 机构名称：永拓会计师事务所（特殊普通合伙） 成立日期：201 ...

上海复旦复华科技股份有限公司董事会 2025 年 4 月 28 日 上海复旦复华科技股份有限公司第十一届董事会 关于前期会计差错更正及追溯调整的说明 （以下无正文） 上海复旦复华科技股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日 召开第十一届董事会第十一次会议，会议审议通过了《关于前期会计差错更正及 追溯调整的议案》，根据相关规定，公司第十一届董事会就本次前期会计差错更 正及追溯调整事项说明如下： 本次前期会计差错更正及追溯调整符合《企业会计准则第 28 号——会计政 策、会计估计变更和差错更正》、中国证券监督管理委员会《公开发行证券的公 司信息披露编报规则第 19 号——财务信息的更正及相关披露》等相关文件的规 定，更正后的财务数据及财务报表能够更真实、全面、客观地反映公司的财务状 况和经营成果，不存在损害公司和全体股东利益的情形，同意本次前期会计差错 更正及追溯调整事项。 董事长:宋 正 董 事:李 燕 董 事:陆 熊 ww 董 事:张静媛 独立董事:任永康 独立董事:倪 薇 独立董事:赵向雷 （本页无正文，系《上海复旦复华科技股份有限公司第十一届董事会关于前期 会计差错更正及追溯调整 ...

Financial Performance - The net profit attributable to shareholders for 2024 is a loss of RMB -133,209,876.48, with retained earnings at RMB -210,842,769.27 as of December 31, 2024[3]. - The basic earnings per share for 2024 is -0.195, a significant decrease from -0.032 in 2023[18]. - The operating revenue for 2024 is RMB 645,322,768.13, down 5.05% from RMB 679,678,938.29 in 2023[20]. - The net cash flow from operating activities for 2024 is RMB -14,439,859.13, a decline of 305.29% compared to RMB 7,033,862.40 in 2023[20]. - The total assets decreased by 19.52% to RMB 1,424,140,492.46 in 2024 from RMB 1,769,467,818.60 in 2023[20]. - The weighted average return on equity for 2024 is -18.84%, compared to -2.77% in 2023[18]. - The company plans no profit distribution or capital reserve transfer due to the loss in 2024[3]. - The net profit attributable to shareholders after deducting non-recurring gains and losses is RMB -136,972,864.12, compared to RMB -50,129,141.81 in 2023[20]. - The company reported a significant impairment provision for inventory by its subsidiary, which contributed to the loss[19]. - The company’s net assets attributable to shareholders decreased by 17.96% to RMB 637,446,077.87 as of the end of 2024[20]. Revenue Breakdown - In 2024, the company's operating revenue was CNY 645.32 million, a decrease of 5.05% compared to the previous year[30]. - The pharmaceutical segment generated revenue of CNY 302.37 million, down 11.71% year-on-year, accounting for 46.86% of total revenue[30]. - The net profit from the pharmaceutical segment was CNY -20.53 million, a decrease of CNY 20.54 million compared to the previous year[30]. - Shanghai Zhonghe Software's revenue for 2024 reached CNY 276.70 million, a year-on-year increase of 2.21%, accounting for 42.88% of the company's total revenue; net profit attributable to shareholders decreased by 2.52% to CNY 5.59 million[33]. - The park segment's total revenue for 2024 was CNY 41.88 million, a year-on-year increase of 4.38%, but net profit attributable to shareholders was -CNY 107.27 million, a decrease of CNY 108.41 million compared to the previous year[35]. Market Challenges - The company faced significant challenges due to policy changes in the pharmaceutical industry, including the normalization of centralized procurement and adjustments to the medical insurance drug list[31]. - The average price reduction for the tenth batch of national organized drug procurement reached approximately 70%, with the highest reduction at 96%[96]. - The national drug procurement policy has been institutionalized, focusing on reducing drug prices while ensuring supply and quality[105]. - The pharmaceutical sector faces risks from policy changes, price reductions, and rising production costs, necessitating strategic adjustments[164]. Research and Development - The company has initiated two new product projects and is increasing R&D investment to enhance product development[31]. - The company is focusing on specialized drugs in areas such as digestive, neurological, anti-tumor, and circulatory system treatments[48]. - The company is committed to improving its quality management system in compliance with the Drug Administration Law[31]. - The company’s R&D investment amounted to 2,666.49 million RMB, representing 6.84% of its operating revenue and 5.52% of its net assets[124]. - The company has increased its R&D focus on generic drug quality and efficacy consistency evaluations, particularly in the field of neurological medications[124]. Strategic Initiatives - The company is focusing on expanding its market presence in pharmaceuticals, software, and park operations while enhancing core business capabilities[30]. - The company is actively researching and planning the layout and expansion of park business in Fengxian, integrating its pharmaceutical and software operations[36]. - The company is exploring strategic collaborations and acquisitions to support its growth and market expansion initiatives[108]. - The company plans to enhance its technological capabilities and expand its market presence in the industrial internet sector[56]. Governance and Compliance - The company maintains independence from its controlling shareholder, ensuring no interference in operational decisions[173]. - The company strictly adheres to information disclosure regulations, ensuring timely and accurate reporting to all shareholders[175]. - The company has established a robust internal control system to enhance management and risk prevention capabilities[174]. - The board of directors consists of nine members, including three independent directors, meeting legal requirements and ensuring effective governance through various committees[172]. Employee and Management - The company employs a total of 1,414 staff members, with 60 in the parent company and 1,354 in major subsidiaries[197]. - The technical personnel comprised 936 employees, representing approximately 66% of the total workforce[197]. - The company has implemented a compensation policy linking employee income to individual performance and company growth[198]. - The remuneration for senior management is linked to the company's performance evaluation[188]. Future Outlook - The company projects a total revenue of 720 million yuan and operating costs of 430 million yuan for 2025, with expenses estimated at 290 million yuan[158]. - The company aims to strengthen its financial performance and operational efficiency in the next fiscal year[182]. - The company is committed to increasing R&D investment and enhancing production efficiency to maintain competitiveness in the pharmaceutical market[160]. - The company is actively involved in research and development of new technologies to drive future growth[182].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 160,921,239.79, representing a 3.50% increase compared to CNY 155,481,059.50 in the same period last year[4] - The net profit attributable to shareholders of the listed company was a loss of CNY 8,124,350.92, an improvement from a loss of CNY 11,103,708.12 in the previous year[4] - The net cash flow from operating activities was a negative CNY 12,297,098.90, significantly improved from a negative CNY 44,759,734.75 in the same period last year[4] - Total operating revenue for Q1 2025 was CNY 160,921,239.79, an increase of 3.5% compared to CNY 155,481,059.50 in Q1 2024[20] - Net profit for Q1 2025 was a loss of CNY 8,241,795.37, an improvement from a loss of CNY 11,140,434.51 in Q1 2024[21] - The net cash flow from operating activities for Q1 2025 was a negative CNY 12,297,098.90, compared to a negative CNY 44,759,734.75 in Q1 2024, indicating a significant reduction in cash outflow[25] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,475,883,220.15, reflecting a 3.63% increase from CNY 1,424,140,492.46 at the end of the previous year[5] - Total current assets amounted to ¥790,428,780.05, up from ¥732,584,482.39, reflecting a growth of 7.9%[15] - The company's total assets reached ¥1,475,883,220.15, compared to ¥1,424,140,492.46, indicating an increase of 3.6%[15] - Short-term borrowings increased to ¥400,250,000.00 from ¥314,620,000.00, representing a rise of 27.2%[16] - Total liabilities rose to ¥804,607,165.99, up from ¥746,572,294.72, marking an increase of 7.8%[16] - The company's equity decreased slightly to ¥679,346,942.00 from ¥684,712,010.00, a decline of 0.5%[16] Shareholder Information - The equity attributable to shareholders of the listed company decreased by 0.97% to CNY 631,271,378.74 from CNY 637,446,077.87 at the end of the previous year[5] - Basic and diluted earnings per share were both CNY -0.0120, an improvement from CNY -0.0162 in the same period last year[5] - The total number of ordinary shareholders at the end of the reporting period was 78,478[10] Cash Flow and Financing - Cash inflow from financing activities in Q1 2025 totaled CNY 217,880,000.00, compared to CNY 108,146,444.33 in Q1 2024, showing a substantial increase of 101.5%[25] - The company reported cash and cash equivalents of ¥156,919,426.12 as of March 31, 2025, an increase of 68.9% from ¥92,749,298.70 on December 31, 2024[14] - Net cash flow from financing activities was $77.93 million, a significant improvement compared to a net outflow of $23.22 million in the previous period[26] - The total cash and cash equivalents at the end of the period increased to $156.61 million, up from $233.66 million at the end of the previous period[26] - Cash outflows from financing activities totaled $139.95 million, slightly higher than $131.36 million in the previous period[26] Government Subsidies and R&D - The company recognized government subsidies amounting to CNY 3,649,213.62, which positively impacted the financial results[6] - Research and development expenses for Q1 2025 were CNY 6,453,958.83, down from CNY 8,191,675.26 in Q1 2024, reflecting a decrease of 21.2%[21] Market and Product Development - The company has no significant new product launches or technological developments reported in the current period[13] - There are no updates on market expansion or mergers and acquisitions in the latest financial report[13] Other Comprehensive Income - Other comprehensive income for Q1 2025 was CNY 1,949,651.79, compared to a loss of CNY -3,537,062.67 in Q1 2024, indicating a positive turnaround[22]

特此公告。 上海复旦复华科技股份有限公司董事会 根据上海证券交易所发布的上市公司分行业信息披露指引《上海证券交易所 上市公司自律监管指引第 3 号——行业信息披露》及《关于做好主板上市公司 2025 年第一季度报告披露工作的重要提醒》相关要求，上海复旦复华科技股份 有限公司下属子公司上海复旦复华药业有限公司 2025 年第一季度主要经营数据 披露如下： 1 主营业务分行业情况 分行业 营业收入 营业成本 毛利率 （%） 营业收入 比上年增 减（%） 营业成本 比上年增 减（%） 毛利率比 上年增减 （%） 药业 72,949,010.38 34,689,081.66 52.45 -5.26 8.18 -5.91 主营业务分产品情况 分产品 营业收入 营业成本 毛利率 （%） 营业收入 比上年增 减（%） 营业成本 比上年增 减（%） 毛利率比 上年增减 （%） 消化系统 药品 33,411,578.68 11,267,124.50 66.28 5.35 13.60 -2.45 神经系统 用药品 19,561,885.06 13,793,474.82 29.49 -17.76 -2.17 -11.23 抗肿瘤药 ...